Bag3, a nucleotide exchange factor of the heat shock protein Hsp70, has been implicated in cell signaling. Here, we report that Bag3 interacts with the SH3 domain of Src, thereby mediating the effects of Hsp70 on Src signaling. Using several complementary approaches, we established that the Hsp70-Bag3 module is a broad-acting regulator of cancer cell signaling by modulating the activity of the transcription factors NF-kB, FoxM1, Hif1a, the translation regulator HuR, and the cell-cycle regulators p21 and survivin. We also identified a small-molecule inhibitor, YM-1, that disrupts the Hsp70-Bag3 interaction. YM-1 mirrored the effects of Hsp70 depletion on these signaling pathways, and in vivo administration of this drug was sufficient to suppress tumor growth in mice. Overall, our results defined Bag3 as a critical factor in Hsp70-modulated signaling and offered a preclinical proofof-concept that the Hsp70-Bag3 complex may offer an appealing anticancer target. Cancer Res; 74(17); 4731-40. Ó2014 AACR.
Introduction
The major heat shock protein Hsp70 (HspA1A) has also been implicated in cancer. Hsp70 is a stress-inducible molecular chaperone that participates in protection of the proteome from aggregation and promotes refolding and degradation of damaged polypeptides (1, 2) . The levels of this protein are highly elevated in a variety of cancers, and correlate with tumor grade, metastasis, chemotherapy resistance, and subsequently, poor prognosis, suggesting that Hsp70 plays a specific role in cancer (3, 4) . Importantly, although Hsp70 is critical for survival of cancer cells, it is dispensable for viability of nontransformed cells (5) . Accordingly, Hsp70 knockout mice are healthy (6) , and the inactivation of Hsp70 manifests serious problems only following a challenge with stress (6, 7), or acute inflammation (8) .
To leverage these observations into therapeutics, several groups have explored the mechanisms by which cancer cells become addicted to Hsp70. On their path to tumorigenesis, cells must escape apoptosis (9) , anoikis (10) , and the harsh conditions of the tumor microenvironment (11) . Although elevated levels of Hsp70 have strong antiapoptotic activity (12, 13) , it is not yet clear whether this function is important for its role in cancer.
Unlike apoptosis, the finding that Hsp70 suppresses cellular senescence has established a clear connection to cancer. Senescence is defined as irreversible cell growth arrest that is associated with assorted cellular changes in morphology and gene expression (14, 15) . Certain oncogenes may trigger senescence, oncogene-induced senescence (OIS), which provides defense against cancer. We have demonstrated that depletion of Hsp70 activates senescence in cells transformed by the oncogenes Her2, PIK3CA, and RAS, but that it has minimal effects in normal cells (16, 17) . Accordingly, Hsp70 knockout mice did not develop breast cancer upon expression of Her2 oncogene (5) . Therefore, Hsp70 could be critical for the escape of transformed cells from OIS, a property that defines its role in tumor initiation.
These properties of Hsp70 suggest that it could be used as a drug target. There have been several attempts to develop inhibitors of Hsp70 for cancer treatment, including inhibitors of substrate binding, for example, aptamers (18) or pifithrin m (19) (20) (21) (22) , or compounds that interact with the ATPase domain, such as VER155008 (23) , MAL3-101 (24) , and YK-5 (25) . However, development of these inhibitors has not reached the clinical trial stage.
To tailor inhibitor development to cancer, specific mechanisms underlying the effects of Hsp70 on tumor development should be defined. In search for these mechanisms, we focused on a nucleotide exchange factor Bag3. This protein contains the Bag domain that binds to a motif in the ATPase domain of Hsp70 proteins (26) , as well as PxxP and WW domains (26) , which may connect it to SH3 domains and PPxY motifs of signaling proteins (27, 28) . Bag3 has been implicated in macroautophagy and aggresome formation (29) (30) (31) . In both processes, Bag3 was proposed to link complexes of Hsp70 with protein aggregates to the autophagic and aggresome machineries. Although it is unknown how Bag3 interacts with the latter, in the process of autophagy, Bag3 uses its WW domain to interact with one of the organizers of the autophagic vacuole SYNPO2 (30) . In addition to its function in recruitment of the Hsp70-bound cargo, it was demonstrated that Bag3 can interact with signaling factors via its PxxP motif (e.g., with PLCg; ref. 32) or WW domain (e.g., with components of the Hippo pathway LATS1 and AMOT1; ref. 30) . Because Bag3 has been implicated in cancer cell motility and invasion (33) (34) (35) , there is a possibility that these effects result from regulation of signaling pathways by Bag3. Interestingly, in the previous studies, the effects of Bag3 on signaling were not connected to effects of Hsp70 on these pathways. Here, we hypothesized that Bag3 could serve as a scaffold with the potential for integrating Hsp70 levels and multiple cancer signaling pathways, and thus mediate effects of Hsp70 on cancer.
Materials and Methods

Cell cultures
MCF10A, HEK293, MCF7, HCT116, B16-F10, and HeLa were from ATCC and initially frozen for storage upon receipt. ATCC authenticates its cell lines using short tandem repeat analysis. Cells were resuscitated and passaged for less than 6 months during use in experiments. MCF10A cells expressing PIK3CA or Her2 were as described before (5, 16, 17) . MCF10A cells were cultivated in Dulbecco's Modified Eagle Medium (DMEM)-F12 medium supplemented with 5% horse serum, hydrocortisone (500 ng/mL), insulin (10 mg/mL), cholera toxin (100 ng/mL), and epidermal growth factor (20 ng/mL). HEK293T cells were maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS). B16-F10, MCF7, and HeLa cells were cultivated in DMEM supplemented with 10% FBS. HCT116 cells were cultured in McCoy 5A medium with 10% FBS. All cultures contained 1% penicillin/ streptomycin.
Mice and xenografts
For xenografts, 500,000 MCF7 cells were mixed at a 1:1 ratio with Matrigel, and 1 million cells were injected subcutaneously in 6-week-old female NCR nude mice (Taconic). For the B16-F10 melanoma allografts, 200,000 cells were injected subcutaneously in hind legs of 6-week-old C57BL6 female mice. Tumor growth was monitored every other day using caliper and calculated according to the formula L Â W 2 Â p/6, where L is length and W is width.
Compounds and antibodies
MG132 was purchased from Biomol and puromycin from Sigma. YM-1 was developed and supplied by Dr. J.E. Gestwicki (University of California at San Francisco, San Francisco, CA). The following antibodies were used: anti-Hsp70 was from Stressgen, anti-Bag3 was a gift from Dr. S. Takayama (Boston University School of Medicine, Boston, MA), anti-p21 and antiHif1a were from BD Pharmingen, anti-b-actin, anti-Src, anti-pSrc (Tyr416), p-NF-kB (Ser536), anti-IkBa, p-paxillin (Tyr118), p-p130Cas (Tyr165, Tyr249, and Tyr410), and p130Cas were from Cell Signaling Technology, anti-FoxM1, anti-HuR, antisurvivin, and anti-Src were from Santa Cruz Biotechnology.
Immunoblotting
Immunoblotting and cell lysate preparations were done according to ref. 5 .
Results
Bag3 mediates effects of Hsp70 on Src activity
To uncover the role of Bag3 and its association with Hsp70 in cancer, we sought to identify SH3 domain-containing signaling factors that can interact with the PxxP motif of Bag3. Accordingly, we performed pull-down experiments using a series of recombinant SH3 domains of various proteins fused to GST. GST-CD40 lacking the SH3 domain was used as a negative control. Lysates with in vitro-translated S 35 -labeled Bag3 were passed over beads carrying various SH3-GST fusion proteins, and bound Bag3 was detected. In the pull-down experiment, Bag3 interacted with SH3 domains of PLCg, Src, c-Abl, c-Grap, Nck, Crk, RasGAP, n-Grab2, and c-Grab2 (Fig. 1A) . These proteins are components of cancer-related pathways, highlighting the potential of Bag3 as a master regulator of cancer signaling. Although any of these signaling proteins may contribute to cancer development, to explore mechanistically how Bag3 regulates signaling, we chose Src as a model.
First, we confirmed that the full-length Src protein interacts with Bag3 in cells. FLAG-labeled Bag3 was coexpressed with Src in 293T cells, precipitated with anti-FLAG antibody, and Src was probed on the blot with anti-Src antibody. Figure 1B , left shows that Src is effectively associated with Bag3. A similar experiment was carried out in HeLa cells to detect association of Bag3 with endogenous Src (Fig. 1B, right) .
Because Bag3 is a cofactor of Hsp70, we further assessed how the ability to interact with Hsp70 influences association of Bag3 with the SH3 domain of Src. Various constructs of Bag3 were expressed, cell lysates were incubated with beads carrying recombinant SH3 domain of Src, and bound Bag3 molecules were detected by immunoblotting. Besides a full-length Bag3 construct, we tested deletions of the PxxP and Bag domains (referred to as FL, DPxxP, and DB, respectively), as well as an R480A mutation, which impairs Bag3 binding to Hsp70 ( Fig. 1C; ref. 36) . The inability of the DB and R480A constructs to bind to Hsp70 was confirmed in the pull-down experiment (Fig. 1D) . The full-length Bag3 effectively interacted with the SH3 domain of Src, and binding was strongly reduced by deletion of the PxxP domain, as expected (Fig. 1E) . Importantly, both DB and R480A constructs also demonstrated reduced binding to the Src-SH3 domain compared with the full-length Bag3, and the effects of these mutations were comparable with the effect of the PxxP deletion (Fig. 1E) . Therefore, interaction with Hsp70 seems to be critical for binding of the PxxP domain of Bag3 with the SH3 domain of Src.
These findings, that the interaction of Bag3 with Src requires the association with Hsp70, suggest that Bag3 may serve as a scaffold, mediating the effects of Hsp70 on signaling pathways, including Src. In line with this hypothesis, knockdown of Hsp70 led to significant activation of Src, as judged by its Y416 phosphorylation ( Fig. 2A) . Furthermore, depletion of Hsp70 increased phosphorylation of downstream Src targets paxillin and p130Cas (Fig. 2B) , confirming Src activation. Interestingly, knockdown of Bag3 did not activate Src; however, it prevented activation of Src upon depletion of Hsp70 ( Fig. 2A) . Therefore, (i) Hsp70 can regulate Src activity, and (ii) this regulation requires Bag3.
To further investigate the role of Hsp70-Bag3 module in Src regulation, we tested effects on Src of Bag3 mutants that are unable to bind to Hsp70. Although overexpression of the fulllength Bag3 did not affect Src activity, overexpression of either the DB or R480A constructs significantly activated endogenous Src in either HeLa or MCF7 cells (Fig. 2C) , further supporting the model.
Hsp70-Bag3 module affects NF-kB
Upon establishing the general mechanistic principle that Hsp70 and Bag3 can cooperate in direct regulation of signaling factors, we further sought to identify a spectrum of cancercontrolling signaling factors regulated by the Hsp70-Bag3 module. We used a combination of two general criteria for such regulation: the signaling factor should be affected (i) by Hsp70 and Bag3 depletion, and (ii) by overexpression of the DB or R480A Bag3 constructs but not of the normal Bag3.
In this search, we used our prior data, where we used microarray analysis to compare gene expression in control and Hsp70-depleted MCF7 cells (Supplementary Table S1 ), followed by gene set enrichment analysis (GSEA). The GSEAbased signal pathway analysis software was developed by the Broad Institute (Cambridge, MA). According to their manual, pathways that show a false discovery rate (FDR) less than 0.25 are significant enough to warrant validation. Our analysis indicated that a large number of pathways were predicted to be up-or downregulated by Hsp70. For example, the proteasome and ubiquitin pathways were strongly upregulated and received the highest scores (see Supplementary Fig. S1A ).
Another pathway that received a high score was the NF-kB (Fig. 3A) and related pathways, such as the IL1R, or TNF pathways ( Supplementary Fig. S1B ). Indeed, using a luciferase reporter under the control of NF-kB, we confirmed that NF-kB activity was increased in Hsp70-depleted cells (Fig. 3B) . Also, levels of IkB were reduced, whereas phosphorylation of the p65 subunit of NF-kB was elevated (Fig. 3C ).
Here, we tested if Bag3 is involved in regulation of NF-kB by Hsp70. Accordingly, Bag3 was depleted in MCF7 cells using shRNA, and the activity of NF-kB was assessed using the luciferase reporter. Unlike Hsp70, depletion of Bag3 had little apparent effect on the activation of NF-kB (Fig. 3B) or the levels of phosphorylated NF-kB p65 subunit (p-S536) and of IkB (Fig. 3C) . On the other hand, in cells with Bag3 depletion, the ability of the knockdown of Hsp70 to activate NF-kB was strongly reduced (Fig. 3B) . Therefore, as with Src regulation, the Hsp70-Bag3 module is critical for regulation of NF-kB.
Notably, it was previously reported that that Bag3 regulates NF-kB by controlling IKKg stability (37), but we were unable to detect any change in IKKg levels following Bag3 depletion (Fig. 3C) . On the other hand, a recent proteomics study (38) indicated that Bag3 can directly interact with IkB, which is consistent with our finding that the Hsp70-Bag3 module affects IkB levels ( Fig. 3B and C) . Because the unbiased approach with GSEA produced only limited information about signaling network regulated by the Hsp70-Bag3 module, in further search for factors regulated by this module, we used a more biased approach based on hints obtained in our prior findings. Accordingly, we decided to test if the regulation of previously identified Hsp70-controlled signaling factors also involved Bag3. In studies of the OIS and tumor initiation, we reported that depletion of Hsp70 affects two important signaling proteins that control growth of cancer cells: the cell-cycle inhibitor p21 and the regulator of mitosis, survivin (5, 17) . To test if Bag3 is also involved in control of these factors, we investigated whether depletion of Bag3 in MCF7 using shRNA affects levels of p21 and survivin. As with knockdown of Hsp70, Bag3 targeting resulted in decreased levels of survivin, and accumulation of p21 (Fig. 3D, top) . Similar effects of Hsp70 and Bag3 depletion were seen in HeLa cells (Fig. 3E ) and the colorectal carcinoma cell line, HCT116 (Supplementary Fig. S2 ), demonstrating that these effects are related to multiple cancer types. Bag3 depletion paralleled the effects of Hsp70 knockdown in all three cell lines, further supporting the idea that Hsp70 and Bag3 are coregulators of these pathways. In line with this suggestion, overexpression of the DB and R480A Bag3 mutants, but not normal Bag3, in HeLa cells mimicked effects of Hsp70 depletion on survivin (Fig.  3F) . In this experiment, we were unable to assess effects on Bag3 mutants on p21, because levels of this protein in HeLa cells were undetectable.
Because both p21 and survivin have a common transcriptional regulator, FoxM1, we tested whether the Hsp70-Bag3 module can control this cancer-regulating factor. Indeed, depletion of either Hsp70 or Bag3 led to strong downregulation of FoxM1 (Fig. 3D, top) and upregulation of its distinct downstream target, the cell-cycle inhibitor p27 (39) . Furthermore, although the levels of FoxM1 were unaltered in normal Bag3 and empty vector control conditions, the DB or R480A Bag3 mutants caused strong downregulation of FoxM1 (Fig. 3F) , indicating the importance of Hsp70-Bag3 interaction in expression of this major transcription factor. Because FoxM1 plays multiple roles in OIS, metastasis, and invasion (40), these findings further support a broad role for the Hsp70-Bag3 module in tumorigenesis.
On the basis of our prior study that connected the stress response to the translation factor HuR, another major player in cancer development (41, 42) , we also suggested that the Hsp70-Bag3 module may affect this pathway. Depletion of either Hsp70 or Bag3 led to significant downregulation of HuR (Fig. 3D, top) . Furthermore, although the levels of HuR were unaltered in normal Bag3 and empty vector control conditions, the DB or R480A Bag3 mutants caused strong downregulation of HuR, indicating that interaction between Hsp70 and Bag3 is important for regulation of this major cancer regulator (Fig.  3F ). In addition, we considered whether one of HuR's translational targets, Hif1a, which is yet another major transcription factor involved in cancer, might also be downregulated. Because levels of Hif1a depend on the availability of oxygen, control, Hsp70-depleted, and Bag3-depleted cells were treated with either hypoxia mimetic deferoxamine, or proteasomal inhibitor MG-132, both of which stabilize Hif1a. Hsp70-depleted or Bag3-depleted MCF7 cells had significantly reduced levels of Hif1a compared with control cells (Fig. 3D, bottom) . Furthermore, Hsp70 depletion strongly reduced expression of a major Hif1 downstream target gene VEGF (Fig. 3G) . Therefore, it seems that the entire signaling network that controls multiple processes in cancer development, including growth, invasion, and angiogenesis, involving HuR, Hif1a, and VEGF, is regulated by Bag3 and Hsp70. It should be noted that only with Src did we identify a direct connection to the Hsp70-Bag3 module biochemically. With other pathways, genetic data do not establish the direct interaction, and therefore these interactions could be mediated by additional factors that can bind to WW or PxxP motifs on Bag3.
In summary, the Hsp70-Bag3 module is involved in regulating a complex network of pathways, including Src, NFkB, FoxM1, survivin, p21, p27, HuR, Hif1a, and most likely, other pathways, all of which play a role in cancer development. When individually considered, these pathways could have cancer-promoting or cancer-repressing effects. Nevertheless, we know that in breast cancer models, depletion of Hsp70 suppresses both tumor initiation and progression (5), indicating that the net outcome of this complex Hsp70-Bag3-controlled signaling network to be prooncogenic.
Disruption of the Hsp70-Bag3 complex by a small molecule mimics effects of Hsp70 depletion on signaling and cancer
Here, we predicted that blocking interaction between Hsp70 and Bag3 could mimic depletion of Hsp70 and have anticancer effects. We focused on an inhibitor of Hsp70, termed YM-1 (43, 44) . To test if YM-1 might disrupt the Hsp70-Bag3 interaction, we immobilized Hsp70 on beads and measured its binding to fluorescently labeled Bag3 using a flow cytometry protein interaction assay (FCPIA). YM-1 strongly inhibited the interaction between Hsp70 and Bag3 (IC 50 , $5 mmol/L; Fig. 4A ). This activity was consistent with the ability of YM-1 to bind to a conserved, allosteric pocket in Hsp70, which traps the chaperone in an ADP-bound form that has weak affinity for Bag3 (43, 44) . To test if YM-1 can disrupt the Hsp70-Bag3 interaction in cells, Hsp70 was immunoprecipitated from HeLa cells treated with YM-1 or a vehicle control, and immunoblotted for Bag3. YM-1 almost completely blocked binding of Hsp70 to Bag3 in cells (Fig.  4B) , indicating that YM-1 is a good chemical probe for addressing the importance of the Hsp70-Bag3 interaction in cancer signaling.
Next, MCF7 and HeLa cells were treated with YM-1 and the activities of signaling pathways were assessed. To determine the appropriate dosage, a range of concentrations were tested ( Supplementary Fig. S3 ). The concentrations of YM-1 used for testing effects on signaling pathways are described in the legend to Fig. 4 , but represent the minimal dose necessary to see an effect in the appropriate cell line. As predicted, YM-1 diminished the FoxM1 and Hif1a pathways, while activating Src (Fig. 4C) , further supporting a role for the Hsp70-Bag3 interaction in cancer signaling. As a further test of this model, we examined the effects of the small-molecule inhibitor myricetin, which inhibits Hsp70, through a different mechanism that involves the Hsp40 family of cochaperones (45), and does not hinder Bag3 binding to Hsp70. Unlike YM-1, myricetin had no significant effects on the signaling pathways (Table 1) , highlighting the specific role of the Hsp70-Bag3 interaction.
Because many of the Hsp70-Bag3-regulated pathways affect cell growth and survival, and depletion of Hsp70 is detrimental for cancer cells specifically due to oncogene signaling (5), we compared effects of YM-1 on viability of nontransformed MCF10A human breast epithelial cells and MCF10A derivatives transformed with either Her2 or PIK3CA oncogenes (Fig. 5A) . Here, cells expressing oncogenes were more sensitive to YM-1 than untransformed MCF10A cells (Fig. 5A) .
To test the effects of YM-1 in vivo, we used the xenograft model with MCF7 cells, which we previously showed lose the ability to develop tumors upon depletion of Hsp70 (5). MCF7 cells were transplanted subcutaneously into nude mice, and when tumors reached the palpable stage, animals were injected intraperitoneally with 25 mg/kg YM-1 or saline. The injections were injected three times every second day, and tumor growth was monitored by caliper. Figure 5B shows that administration of YM-1 dramatically inhibited tumor growth. There were no apparent effects of the drug on the health and vitality of the animals at the effective doses used. In fact, they were more alert than untreated animals due to the lower tumor burden. The inhibition of tumor growth by the drug closely correlated with suppression of FoxM1, downregulation of survivin, and induction of p21 (Fig. 5C and Supplementary S4 ). The Hif1a pathway could not be assessed in this experiment because the levels of Hif1 were undetectable in either na€ ve or YM-1-treated animals. We also tested effects of YM-1 on a distinct tumor model, allograft tumor of B16 melanoma cells. B16 cells were transplanted subcutaneously into nude mice, and at day 7 posttransplantation (day 0 on the graph; Fig. 5B , right), animals were injected intraperitoneally with 25 mg/kg YM-1 or saline. The injections were injected three times every second day, and tumor growth was monitored by caliper. As seen in Fig. 5B , administration of YM-1 significantly reduced tumor growth. Therefore, YM-1 showed a predictable response in animals, which correlated with strong suppression of growth of two distinct tumor types with minimal normal tissue toxicity.
Discussion
Here, we investigated potential mechanisms of regulation of cancer signaling by Hsp70. We specifically focused on Bag3, the member of the Bag family proteins that functions in Hsp70 nucleotide exchange. The focus was defined by prior reports that Bag3 can interact with signaling molecules, via its PxxP and WW domains. In other words, via its Bag domain, Bag3 may regulate the chaperone activity of Hsp70 by controlling the ADP/ATP exchange, and via PxxP and WW motifs, it can also regulate activities of important signaling pathways. Therefore, Bag3 may potentially be able to integrate the Hsp70 chaperone network with a network of signaling pathways. Using both biochemical and genetic approaches, we demonstrated that effects of Hsp70 in regulation of signaling are mediated by Bag3. Surprisingly, whereas depletion of Bag3 had similar effects on some signaling pathways as depletion of Hsp70 (e.g., on FoxM1 or Hif1a), in other cases, depletion of Bag3 did not affect signaling but was necessary for Hsp70 effects (e.g., with NF-kB or Src). Therefore, in control of signaling pathways by Bag3-Hsp70 pair, each individual target may be subject to specific regulatory mechanisms. Although more work is needed, we suggest that these differences could be related to specific ways in which the signaling modules interact with Bag3. For example, whereas the Bag3 regulation of Src is mediated by the PxxP domain, the interaction with other pathways could be through the WW or M domains.
We undertook several unbiased and biased approaches to dissect cancer-related pathways regulated by the Hsp70-Bag3 module. We observed that Hsp70-Bag3 controls activities of multiple signaling factors that are involved in cancer development. The number of the factors was relatively large, consistent with a broad "hub" role for Hsp70 in cancer. We validated a subset of these pathways, and found that Hsp70 depletion downregulates Hif1a and FoxM1, whereas upregulating the NF-kB pathways. Interestingly, the former effects would presumably be anticancerous, whereas the latter is likely to be cancer-promoting. These disparate responses to the same stimulus should not be very surprising because similar phenomena have been observed with other anticancer treatments. For example, radiation triggers the anticancer p53 pathway and also cancer-promoting NF-kB and c-Abl (46, 47) . In this case and in the case of Hsp70 depletion, the net effect is anticancerous.
Previously, Hsp70 knockout was shown to prevent development of Her2-positive tumors in a mouse model by suppressing OIS (5), indicating that Hsp70 plays an important role at the early stages of tumor development. Our findings that the Hsp70-Bag3 module affects pathways regulating angiogenesis and invasion (e.g., Hif1a or FoxM1), suggest that Hsp70 may play a broader role in cancer development. Although it has been reported that Hsp70 is seen at elevated levels in low-grade tumors (48) curiously, the levels of Hsp70 increase further in high-grade cancers (3, 4) , consistent with distinct role(s) of Hsp70 in later stages of cancer progression, such as invasion.
Overall, this work pointed to a key role for the Hsp70-Bag3 complex in cancer, and suggests that this pair may represent a promising drug target. Of the available Hsp70 inhibitors, YM-1 is a unique probe because it specifically traps the ADP-bound form of Hsp70 (43) . These observations suggested to us that YM-1 might block the Hsp70-Bag3 interaction because Bag3 has a weak affinity for the ADP-bound form of Hsp70 and it normally favors client release (J.E. Gestwicki; manuscript in preparation). Thus, although the known binding site for YM-1 is more than 20 Å from the contact surface between Hsp70 and Bag3, allosteric regulation of Hsp70 by YM-1 would be predicted to interrupt nucleotide exchange factor binding. Accordingly, YM-1 has a mechanism of action that is unique among the known Hsp70 inhibitors, which positions it to destabilize Hsp70-Bag3 activities in cancer cells, leading to suppression of cancer-promoting signaling pathways. Consistently, YM-1 had anticancer activity in cells and in a xenograft model. These results validate the Hsp70-Bag3 complex as a potential anticancer target.
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